Deal or No Deal, AstraZeneca Stock Is a Bargain
The logic of a pharma megamerger is questionable, but AstraZeneca’s record isn’t.
We haven't written up this one. WSJ Markets has the full story — the link below goes straight to it.
More in Health & Medicine
West Nile virus spreads in Europe? Greece reports surge, Italy leads infections, first case in Germany
Greece and Italy are reporting the highest West Nile virus activity in Europe this season.
Tanzania: EACOP Injects 2.8bn/ - Into Health Projects in Tanga, Geita
[Daily News] Dar es Salaam -- THE East African Crude Oil Pipeline (EACOP) has committed more than 2.8bn/- (1.06 million US dollars) to construct two health centres and expand emergency healthcare…
Perez Hilton family says he is 'able to communicate'
Perez Hilton's family have said he is "able to communicate" after his admission to hospital.
Supreme Court denies Asaram medical bail, allows round-the-clock caretaker in jail
Asaram’s counsel told the court that his health was deteriorating and that he was suffering from multiple ailments, including coronary artery disease, thalassemia and recurrent blood loss.
PM reviews plans for two $5bn medical cities in New Capital, New Alamein
Prime Minister Mostafa Madbouly reviewed a proposal to establish two integrated medical cities in the New Capital and New Alamein City as the government moves forward with plans to develop large-scale…
AstraZeneca may buck a decade of pharma strategy to buy U.S. scale
Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma consolidation.